In this video, Matthew R. Zibelman, MD, discusses the A-DREAM trial, which found that androgen deprivation therapy ...

In this video, Andre Kydd, MD, PhD, discusses highlights in the field of prostate cancer, including biomarkers of response in treatment and data on new classes of therapeutic agents, presented at ASCO ...

In this post, we will show you how to create a video with Copilot AI. If you’ve been using Microsoft Copilot mainly for drafting emails, summarizing content, or analyzing data, there’s a powerful new ...

Is that YouTube video clip you’re watching real or was it made with AI? YouTube wants to make it easier for viewers to know when content on its platform is AI-generated. In 2024, it started labeling ...

YouTube has announced improved AI labels for videos as part of a movie to add transparency to content made with generative AI. Anyone who’s used YouTube recently will no doubt be aware of the increase ...

AI content creation tools like Google’s new Omni model threaten to make reality even harder to discern from AI fantasy, but YouTube is taking an important step toward verifying video origins. After ...

The Google-owned video platform also now has more three billion users, the company revealed Tuesday. By Alex Weprin Senior Editor Sora may be dead, but some of its most buzzed-about features are about ...

ANN ARBOR, MI — A University of Michigan Health center is using artificial intelligence to help plan treatments for prostate cancer. The UM Health Weiser Center for Prostate Cancer in Ann Arbor ...

In the process of converting carbon dioxide into useful chemicals such as ethylene—a key precursor for plastics—a major challenge has been the flooding of electrodes, where electrolyte penetrates the ...

Add Futurism (opens in a new tab) More information Adding us as a Preferred Source in Google by using this link indicates that you would like to see more of our content in Google News results. If ...

Pfizer is eyeing an earlier use of its PARP inhibitor Talzenna after a positive phase 3 trial in metastatic hormone-sensitive prostate cancer (mHSPC). The phase 3 Talapro-3 trial met its primary ...